Musculoskeletal Oncologic Interventions: Proceedings from the Society of Interventional Radiology and Society of Interventional Oncology Research Consensus Panel

Anil Nicholas Kurup, Jack W. Jennings, Sean Tutton, Alda L. Tam, Alexis Kelekis, Bradford J. Wood, Damian E. Dupuy, Alessandro Napoli, Sean S. Park, Steven I. Robinson, Peter S. Rose, Michael C. Soulen, Sarah B. White, Matthew R. Callstrom

Research output: Contribution to journalEditorialpeer-review

Abstract

Musculoskeletal interventions are increasingly used with palliative and curative intent in the multidisciplinary treatment of oncology patients with bone and soft-tissue tumors. There is an unmet need for high-quality evidence to guide broader application and adoption of minimally invasive interventional technologies to treat these patients. Therefore, the Society of Interventional Radiology Foundation and the Society of Interventional Oncology collaborated to convene a research consensus panel to prioritize a research agenda addressing the gaps in the current evidence. This article summarizes the panel's proceedings and recommendations for future basic science and clinical investigation to chart the course for interventional oncology within the musculoskeletal system. Key questions that emerged addressed the effectiveness of ablation within specific patient populations, the effect of combination of ablation with radiotherapy and/or immunotherapy, and the potential of standardization of techniques, including modeling and monitoring, to improve the consistency and predictability of treatment outcomes.

Original languageEnglish (US)
Pages (from-to)1089.e1-1089.e9
JournalJournal of Vascular and Interventional Radiology
Volume32
Issue number7
DOIs
StatePublished - Jul 2021

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Musculoskeletal Oncologic Interventions: Proceedings from the Society of Interventional Radiology and Society of Interventional Oncology Research Consensus Panel'. Together they form a unique fingerprint.

Cite this